FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2771424111> ?p ?o ?g. }

• W2771424111 endingPage "e0187537" @default.
• W2771424111 startingPage "e0187537" @default.
• W2771424111 abstract "Aim The association between dipeptidyl peptidase-4 inhibitors (DPP-4is), a class of anti-diabetes, and bone fracture in patients with type 2 diabetes mellitus (T2DM) is unknown. This meta-analysis aimed to systematically evaluate the effects of DPP-4is on bone fracture in T2DM patients. Methods We searched the Cochrane Library, Embase, Medline and ClinicalTrials.gov from inception through April 28th, 2016 to identify randomized controlled trials (RCTs) that compared DPP-4is with placebo or other anti-diabetes in T2DM patients. RCTs lasting more than 12 weeks and having data on bone fracture were included. We conducted random-effects meta-analysis to estimate odds ratios (ORs) and their 95% confidence intervals (CIs), and network meta-analysis (NMA) to supplement direct comparisons. Predictive interval plot and node-splitting method were used to evaluate the heterogeneity and inconsistency for NMA, while the funnel plot was applied to explore publication bias. Besides, study quality was assessed according to Cochrane risk of bias tool. Results We identified 75 RCTs with a total of 70,207 patients and 11 treatments: interventions included 5 DPP-4is (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin), while controls included placebo and 5 other anti-diabetes (sulfonylureas, glucagon-like peptide-1 receptor agonists, metformin, thiazolidinediones, sodium-glucose co-transporter 2 inhibitors). In the NMA, the risk of fracture for alogliptin tended to decrease when versus placebo (OR, 0.51; 95% CI, 0.29 to 0.88). Besides, aloglitpin had a lower risk compared with linagliptin (OR, 0.45; 95% CI, 0.20 to 0.99) and saxagliption (OR, 0.46; 95%CI, 0.25 to 0.84); the risk was higher with saxagliptin when versus sitagliptin (OR, 1.90; 95% CI, 1.04 to 3.47) and sulfonylureas (OR, 1.98; 95% CI, 1.06 to 3.71). In the direct pairwise meta-analysis, alogliptin was associated with a non-significant tendency to reduction of bone fracture compared with placebo (OR, 0.54; 95% CI, 0.29 to 1.01). Ranking probability analysis indicated alogliptin decreased the risk of bone fracture most with a probability of 76.3%. Conclusion Alogliptin may be associated with a lower risk of bone fracture compared with placebo, linagliptin, or saxagliptin, while other anti-diabetes did not seem to have an association with the risk of bone fracture." @default.
• W2771424111 created "2017-12-22" @default.
• W2771424111 creator A5005170922 @default.
• W2771424111 creator A5013213475 @default.
• W2771424111 creator A5016012630 @default.
• W2771424111 creator A5018869790 @default.
• W2771424111 creator A5022943551 @default.
• W2771424111 creator A5028813896 @default.
• W2771424111 creator A5064190054 @default.
• W2771424111 creator A5070369468 @default.
• W2771424111 creator A5080038308 @default.
• W2771424111 date "2017-12-05" @default.
• W2771424111 modified "2023-10-13" @default.
• W2771424111 title "The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials" @default.
• W2771424111 cites W1143626075 @default.
• W2771424111 cites W1486033897 @default.
• W2771424111 cites W1502015718 @default.
• W2771424111 cites W1811061299 @default.
• W2771424111 cites W1842290562 @default.
• W2771424111 cites W1902576439 @default.
• W2771424111 cites W1951484771 @default.
• W2771424111 cites W1967046314 @default.
• W2771424111 cites W1967861795 @default.
• W2771424111 cites W1973914781 @default.
• W2771424111 cites W1978574536 @default.
• W2771424111 cites W1980666755 @default.
• W2771424111 cites W1987012320 @default.
• W2771424111 cites W1987081198 @default.
• W2771424111 cites W1994744900 @default.
• W2771424111 cites W1994832750 @default.
• W2771424111 cites W2002961599 @default.
• W2771424111 cites W2004021898 @default.
• W2771424111 cites W2006573193 @default.
• W2771424111 cites W2016632734 @default.
• W2771424111 cites W2032970094 @default.
• W2771424111 cites W2037593179 @default.
• W2771424111 cites W2057044572 @default.
• W2771424111 cites W2062951654 @default.
• W2771424111 cites W2064947912 @default.
• W2771424111 cites W2076599880 @default.
• W2771424111 cites W2077165978 @default.
• W2771424111 cites W2084074115 @default.
• W2771424111 cites W2089642160 @default.
• W2771424111 cites W2090111195 @default.
• W2771424111 cites W2097832687 @default.
• W2771424111 cites W2103075451 @default.
• W2771424111 cites W2109434372 @default.
• W2771424111 cites W2111178315 @default.
• W2771424111 cites W2125435699 @default.
• W2771424111 cites W2125637498 @default.
• W2771424111 cites W2126930838 @default.
• W2771424111 cites W2127854619 @default.
• W2771424111 cites W2129821518 @default.
• W2771424111 cites W2140699272 @default.
• W2771424111 cites W2147618898 @default.
• W2771424111 cites W2151976861 @default.
• W2771424111 cites W2152839864 @default.
• W2771424111 cites W2156150085 @default.
• W2771424111 cites W2157823046 @default.
• W2771424111 cites W2161817962 @default.
• W2771424111 cites W2217945799 @default.
• W2771424111 cites W2279665455 @default.
• W2771424111 cites W2343730112 @default.
• W2771424111 cites W2400312863 @default.
• W2771424111 cites W2463846283 @default.
• W2771424111 cites W2469016626 @default.
• W2771424111 cites W2475461556 @default.
• W2771424111 cites W2483090964 @default.
• W2771424111 cites W2542526844 @default.
• W2771424111 doi "https://doi.org/10.1371/journal.pone.0187537" @default.
• W2771424111 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5716604" @default.
• W2771424111 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29206832" @default.
• W2771424111 hasPublicationYear "2017" @default.
• W2771424111 type Work @default.
• W2771424111 sameAs 2771424111 @default.
• W2771424111 citedByCount "31" @default.
• W2771424111 countsByYear W27714241112018 @default.
• W2771424111 countsByYear W27714241112019 @default.
• W2771424111 countsByYear W27714241112020 @default.
• W2771424111 countsByYear W27714241112021 @default.
• W2771424111 countsByYear W27714241112022 @default.
• W2771424111 countsByYear W27714241112023 @default.
• W2771424111 crossrefType "journal-article" @default.
• W2771424111 hasAuthorship W2771424111A5005170922 @default.
• W2771424111 hasAuthorship W2771424111A5013213475 @default.
• W2771424111 hasAuthorship W2771424111A5016012630 @default.
• W2771424111 hasAuthorship W2771424111A5018869790 @default.
• W2771424111 hasAuthorship W2771424111A5022943551 @default.
• W2771424111 hasAuthorship W2771424111A5028813896 @default.
• W2771424111 hasAuthorship W2771424111A5064190054 @default.
• W2771424111 hasAuthorship W2771424111A5070369468 @default.
• W2771424111 hasAuthorship W2771424111A5080038308 @default.
• W2771424111 hasBestOaLocation W27714241111 @default.
• W2771424111 hasConcept C126322002 @default.
• W2771424111 hasConcept C134018914 @default.
• W2771424111 hasConcept C142724271 @default.
• W2771424111 hasConcept C168563851 @default.
• W2771424111 hasConcept C204787440 @default.

• next